company background image
874 logo

Guangzhou Baiyunshan Pharmaceutical Holdings SEHK:874 Rapport sur les actions

Dernier prix

HK$19.24

Capitalisation boursière

HK$49.0b

7D

-2.8%

1Y

-8.8%

Mise à jour

24 Aug, 2024

Données

Finances de l'entreprise +

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

SEHK:874 Rapport sur les actions

Capitalisation boursière : HK$49.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

874 Aperçu des actions

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, avec ses filiales, recherche, développe, fabrique et vend des médicaments chinois brevetés et occidentaux, des matières premières chimiques, des médicaments naturels et biologiques, et des intermédiaires de matières premières chimiques en République populaire de Chine et à l'étranger.

874 analyse fondamentale
Score flocon de neige
Évaluation5/6
Croissance future1/6
Performances passées2/6
Santé financière5/6
Dividendes4/6

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Concurrents

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Guangzhou Baiyunshan Pharmaceutical Holdings
Historique des cours de bourse
Prix actuel de l'actionHK$19.24
Plus haut sur 52 semainesHK$24.20
Plus bas sur 52 semainesHK$18.48
Bêta0.56
1Variation sur 1 mois-4.04%
Variation sur 3 mois-14.11%
Variation sur 1 an-8.82%
3Variation sur 3 ans-2.93%
Variation sur 5 ans-34.45%
Évolution depuis l'introduction en bourse1,335.82%

Nouvelles et mises à jour récentes

A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Jul 15
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down

Jun 26
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227

Jun 03
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227

Recent updates

A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Jul 15
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down

Jun 26
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227

Jun 03
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227

The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

May 23
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

May 13
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?

Mar 08
Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price

Feb 23
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward

Feb 10
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward

Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Jan 25
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing

Jan 09
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing

With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Nov 28
With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Nov 15
A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Oct 19
We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes

Oct 03
Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?

Aug 15
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?

Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?

Aug 02
Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?

Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall

Jul 02
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Jun 01
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors

May 01
Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors

The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing

Mar 28
The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

Feb 23
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Jan 23
With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger

Dec 24
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger

Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Nov 24
Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?

Nov 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?

Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Aug 02
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year

May 30
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price

Apr 29
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

Apr 10
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Jan 09
We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet

Oct 11
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Jul 12
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

May 26
Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?

Apr 30
How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate

Apr 08
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate

These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well

Mar 25
These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 02
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain

Feb 11
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?

Jan 26
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?

Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?

Jan 06
Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet

Dec 23
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet

Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Nov 26
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Rendement pour les actionnaires

874HK HealthcareHK Marché
7D-2.8%-4.3%0.3%
1Y-8.8%-29.9%4.0%

Rendement vs Industrie: 874 a dépassé le secteur Hong Kong Healthcare qui a rapporté -30.6 % au cours de l'année écoulée.

Rendement vs marché: 874 a sous-performé le marché Hong Kong qui a rapporté 6.2 % au cours de l'année écoulée.

Volatilité des prix

Is 874's price volatile compared to industry and market?
874 volatility
874 Average Weekly Movement3.7%
Healthcare Industry Average Movement5.6%
Market Average Movement6.3%
10% most volatile stocks in HK Market13.1%
10% least volatile stocks in HK Market3.3%

Cours de l'action stable: 874 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 874 ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
199728,048Hong Liwww.gybys.com.cn

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, avec ses filiales, recherche, développe, fabrique et vend des médicaments chinois brevetés et occidentaux, des matières premières chimiques, des médicaments naturels et biologiques, et des intermédiaires de matières premières chimiques en République populaire de Chine et au niveau international. La société exerce ses activités par l'intermédiaire des segments Great Southern TCM, Great Commerce, Great Health et Other. Elle est également impliquée dans la vente en gros, la vente au détail, la vente, l'importation et l'exportation de médicaments occidentaux et chinois, d'instruments médicaux, de produits pharmaceutiques, d'équipements médicaux et de produits de santé ; dans la recherche et le développement, la production et la vente de boissons, de produits alimentaires, de produits de santé et d'autres produits ; dans la production et la vente d'aliments préemballés, de produits laitiers, etc. En outre, la société investit dans l'industrie de la santé, comme les services médicaux, la gestion de la santé, l'entretien de la santé, les soins aux personnes âgées, etc., et fournit des services de location et commerciaux, de santé, de publicité, de chargement et de déchargement, ainsi que des services d'entreposage.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Guangzhou Baiyunshan Pharmaceutical Holdings se comparent-ils à sa capitalisation boursière ?
874 statistiques fondamentales
Capitalisation boursièreHK$48.97b
Bénéfices(TTM)HK$4.49b
Recettes(TTM)HK$84.07b

7.0x

Ratio P/E

0.4x

Ratio P/S

Le site 874 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
874 compte de résultat (TTM)
RecettesCN¥76.83b
Coût des recettesCN¥62.65b
Marge bruteCN¥14.19b
Autres dépensesCN¥10.08b
Les revenusCN¥4.11b

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

Aug 30, 2024

Résultat par action (EPS)2.53
Marge brute18.46%
Marge bénéficiaire nette5.34%
Ratio dettes/capitaux propres34.2%

Quelles ont été les performances à long terme de 874?

Voir les performances historiques et les comparaisons

Dividendes

4.3%

Rendement actuel des dividendes

30%

Ratio de distribution